Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Participants with a diagnosis of CML-CP who had received prior treatment with 2 or more ATP binding site TKIs and were treatment failure (as per guidelines adapted from the 2013 ELN recommendations) or intolerant to the most recent TKI. Participants were randomized in a 2:1 ratio to asciminib 40 mg BID or bosutinib 500 mg QD. Randomization was stratified by major cytogenetic response (MCyR) at screening. Participants with documented treatment failure (as per the 2013 ELN recommendations) while on bosutinib treatment were offered the option to switch to asciminib treatment within 96 weeks after the last patient was randomized to the study.